Takeda adds $1.5B for new drug buys

Japan's Takeda Pharmaceuticals says it will set aside more than $1.5 billion over the next three years to buy new products. That money will be in addition to the pharma company's regular budget for new drug acquisitions. Yomiuri first reported the news. Report

Suggested Articles

Xcovery's ALK inhibitor shrank tumors in 75% of lung cancer patients, compared to 67% for Pfizer's Xalkori, the first FDA-approved drug of that class.

The FDA accepted the regulatory filing for Biogen's once-failed Alzheimer's drug, aducanumab, with plans to decide its fate by March 7, 2021.

Alexion named a chief diversity officer, while COVID-19 vaccine player has two new members of its C-suite.